Meanwhile, the interaction between KDM5C and ZYMND8 is also important for its function in activating estrogen/ERα‐target genes in breast cancer, and therefore small molecule inhibitor capable of interrupting KDM5C and ZYMND8 interaction will be efficacious in antagonizing the enhancer activation program. Here, ESR1 is linked to breast carcinoma.